biostudies-literatureHammers DBDOD ADNILumosityPfizer Inc.NIBIB NIH HHSNIA NIH HHSAlzheimer's Drug Discovery FoundationCogstateIXICO Ltd.Alzheimer's Association LEADSEisai Inc.GE HealthcareEli Lilly and CompanyCereSpir, Inc.FujirebioTransition TherapeuticsMerck & Co., Inc.Novartis Pharmaceuticals CorporationTakeda Pharmaceutical CompanyEuroImmunAraclon BiotechMeso Scale Diagnostics, LLC.ServierAlzheimer's AssociationNIH HHSJanssen Alzheimer Immunotherapy Research & Development, LLC.Elan Pharmaceuticals, Inc.Neurotrack TechnologiesBioClinica, Inc.AbbVieBristol-Myers Squibb CompanyPiramal ImagingAlzheimer's Disease Neuroimaging InitiativeNeuroRx ResearchGenentech, Inc.BiogenJohnson & Johnson Pharmaceutical Research & Development LLC.F. Hoffmann-La Roche LtdLundbecke14218https://www.ebi.ac.uk/biostudies/studies/S-EPMC11772709biostudies-literatureUnknown21(1)<h4>Introduction</h4>Early-onset Alzheimer's disease (EOAD) and late-onset Alzheimer's disease (LOAD) share similar amyloid etiology, but evidence from smaller-scale studies suggests that they manifest differently clinically. Current analyses sought to contrast the cognitive profiles of EOAD and LOAD.<h4>Methods</h4>Z-score cognitive-domain composites for 311 amyloid-positive sporadic EOAD and 314 amyloid-positive LOAD participants were calculated from baseline data from age-appropriate control cohorts. Z-score composites were compared between AD groups for each domain.<h4>Results</h4>After controlling for cognitive status, EOAD displayed worse visuospatial, executive functioning, and processing speed/attention skills relative to LOAD, and LOAD displayed worse language, episodic immediate Alzheimer's & dementia : the journal of the Alzheimer's AssociationDifferences in baseline cognitive performance between participants with early-onset and late-onset Alzheimer's disease: Comparison of LEADS and ADNI.PMC11772709P30 AG010133P50 AG005146U01 AG057195U01AG6057195P50 AG005681AARG-22-926940W81XWH-12-2-0012P50 AG047366U24 AG021886R56 AG057195U24AG021886P30 AG072976P30 AG066444P50AG047366P50 AG023501LDRFP-21-818464P30 AG013854P50 AG008702GENETICS-19-639372P30 AG010124P30 AG062421P50 AG025688U01 AG016976P30 AG062422P30 AG066506P30AG066506U24 AG072122U01 AG024904Dage JLWomack KApostolova LGMusiek ESalloway SBeckett LDay GSGrant ITaurone ATurner RSClark DGraff-Radford NRWolk DALagarde JHonig LSJones DTRiddle MRogalski ECarrillo MCReman RHammers DBLa Joie RRabinovici GDAisen PKirby KSha SJLEADS Consortium 1 for the Alzheimer's Disease Neuroimaging InitiativeAtri ANudelman KDuara REloyan ADickerson BCMendez MFWingo TSMasdeu JCOnyike CUPolsinelli AJJohnson ECBThangarajah MGao SfalseDifferences in baseline cognitive performance between participants with early-onset and late-onset Alzheimer's disease: Comparison of LEADS and ADNI.<h4>Introduction</h4>Early-onset Alzheimer's disease (EOAD) and late-onset Alzheimer's disease (LOAD) share similar amyloid etiology, but evidence from smaller-scale studies suggests that they manifest differently clinically. Current analyses sought to contrast the cognitive profiles of EOAD and LOAD.<h4>Methods</h4>Z-score cognitive-domain composites for 311 amyloid-positive sporadic EOAD and 314 amyloid-positive LOAD participants were calculated from baseline data from age-appropriate control cohorts. Z-score composites were compared between AD groups for each domain.<h4>Results</h4>After controlling for cognitive status, EOAD displayed worse visuospatial, executive functioning, and processing speed/attention skills relative to LOAD, and LOAD displayed worse language, episodic immediate 2025-01-01T00:00:00Z2025 Jan2025-04-04T23:12:12.572Z2025-04-04T23:12:12.572ZS-EPMC117727093971122810.1002/alz.14218